Department of Abdominal Surgery, University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium.
Institut für Forschung in der Operativen Medizin (IFOM), Witten/Herdecke University, Cologne, Germany.
Ann Surg. 2021 Jan 1;273(1):57-65. doi: 10.1097/SLA.0000000000004062.
The aim of this study was to investigate the approach (open or laparoscopic) and mesh type (synthetic or biological) in ventral hernias in a clean setting.Summary of Background Data: The level of evidence on the optimal surgical approach and type of mesh in ventral hernia repair is still low.
Patients with a ventral abdominal hernia (diameter 4-10 cm) were included in this double-blind randomized controlled trial across 17 hospitals in 10 European countries. According to a 2 × 2-factorial design, patients were allocated to 4 arms (open retromuscular or laparoscopic intraperitoneal, with synthetic or Surgisis Gold biological mesh). Patients and outcome assessors were blinded to mesh type used. Major postoperative complication rate (hernia recurrence, mesh infection, or reoperation) within 3 years after surgery, was the primary endpoint in the intention-to-treat population.
Between September 1st, 2005, and August 7th, 2009, 253 patients were randomized and 13 excluded. Six of 61 patients (9.8%) in the open synthetic mesh arm, 15 of 66 patients (22.7%) in the open biological mesh arm, 7 of 64 patients (10.9%) in the laparoscopic synthetic mesh arm and 17 of 62 patients (27.4%) in the laparoscopic biological mesh arm had a major complication. The use of biological mesh resulted in significantly more complications (P = 0.013), also after adjusting for hernia type, body mass index, and study site. The trial was prematurely stopped due to an unacceptable high recurrence rate in the biological mesh arms.
The use of Surgisis Gold biological mesh is not recommended for noncomplex ventral hernia repair.
This trial was registered at controlled-trials.com (ISRCTN34532248).
本研究旨在探讨清洁环境下腹侧疝的手术入路(开放或腹腔镜)和补片类型(合成或生物)。
在腹侧疝修补术中,关于最佳手术入路和补片类型的证据水平仍然较低。
本双盲随机对照试验纳入了 17 家欧洲医院的 253 例腹侧疝(直径 4-10cm)患者。根据 2×2 析因设计,患者被分配到 4 个组(开放肌后或腹腔镜腹腔内,使用合成或 Surgisis Gold 生物补片)。患者和结果评估者对使用的补片类型均不知情。术后 3 年内主要并发症发生率(疝复发、补片感染或再次手术)是意向治疗人群的主要终点。
2005 年 9 月 1 日至 2009 年 8 月 7 日,253 例患者被随机分组,13 例被排除。开放合成补片组 61 例患者中有 6 例(9.8%)、开放生物补片组 66 例患者中有 15 例(22.7%)、腹腔镜合成补片组 64 例患者中有 7 例(10.9%)和腹腔镜生物补片组 62 例患者中有 17 例(27.4%)发生了主要并发症。使用生物补片导致的并发症明显更多(P=0.013),即使在调整了疝类型、体重指数和研究地点后也是如此。由于生物补片组的复发率过高,试验提前终止。
不推荐在非复杂性腹侧疝修复中使用 Surgisis Gold 生物补片。
本试验在 controlled-trials.com(ISRCTN34532248)注册。